0.5328

4.86% -0.0272

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Discussions Forecast

Caribou Biosciences Inc stock is traded at $0.5328, with a volume of 2.14M. It is down -4.86% in the last 24 hours and down -58.70% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Previous Close:

$0.56

Open:

$0.5499

24h Volume:

2.14M

Relative Volume:

0.63

Market Cap:

$57.12M

Revenue:

$11.16M

Net Income/Loss:

$-148.13M

P/E Ratio:

-0.3354

EPS:

-1.5885

Net Cash Flow:

$-112.35M

1W Performance:

+13.39%

1M Performance:

-58.70%

6M Performance:

-76.42%

1Y Performance:

-78.69%

1-Day Range:

$0.5328

$0.5768

1-Week Range:

$0.4594

$0.5768

52-Week Range:

$0.4425

$3.535

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU Caribou Biosciences Inc	0.5328	57.12M	11.16M	-148.13M	-112.35M	-1.5885
VRTX Vertex Pharmaceuticals Inc	523.93	132.80B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.02	82.88B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	200.10	79.89B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	873.71	54.94B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	377.63	42.72B	5.76B	514.49M	1.10B	4.4813

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-26	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-07-26	Downgrade	Leerink Partners	Outperform → Market Perform
Oct-07-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

Oct 21, 2026

Arcus Biosciences stock falls on public offering announcement - Yahoo Finance Australia

Oct 21, 2026

Oct 13, 2026

Caribou Biosciences (CRBU) Slides 6.44% to $0.46 as Shares Test Key SupportRVOL Breakout - https://www.siam.in/

Oct 13, 2026

Oct 08, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Oct 08, 2026

Oct 07, 2026

OLB Group (OLB) Rally Cools After Hours as Shares Tumble 29%: Here's Why - Benzinga

Oct 07, 2026

Caribou alarm herd, stock plunges on ‘alternatives’ plan - BioWorld News

Oct 07, 2026

OLB Group (OLB) Rally Cools After Hours as Shares Tumble 29%: Here's Why - TradingView

Oct 07, 2026

Oct 06, 2026

A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price. - Stock Titan

Oct 06, 2026

Caribou Biosciences stock plunges 40% on halt of CAR-T programs - Investing.com

Oct 06, 2026

500,000 option-exercise shares are part of an officer's planned sale at Pacific Biosciences (PACB). - Stock Titan

Oct 06, 2026

A director converts a stock grant and holds 141,585 Solid Biosciences (SLDB) shares directly. - Stock Titan

Oct 06, 2026

Option exercises are part of a CEO's proposed share sale at IDEAYA (Nasdaq: IDYA). - Stock Titan

Oct 06, 2026

Apr 09, 2026

Constellation Brands Inc (STZ) Stock Price, Quote, News & History - Benzinga

Apr 09, 2026

Sep 30, 2026

After buying 5,500 shares, Anixa Biosciences (ANIX) CFO holds 50,000 shares directly. - Stock Titan

Sep 30, 2026

Sep 29, 2026

The NYSE notifies regulators of plans to remove Global Business Travel (NYSE: GBTG) Class A shares. - Stock Titan

Sep 29, 2026

Sep 22, 2026

Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - Stock Titan

Sep 15, 2026

Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan

Sep 15, 2026

Sep 14, 2026

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com

Sep 14, 2026

Anixa Biosciences (NASDAQ: ANIX) CEO lifts stake to 665,000 shares - Stock Titan

Sep 14, 2026

Sep 09, 2026

Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan

Sep 09, 2026

Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan

Sep 09, 2026

Sep 03, 2026

OUTFRONT Media (NYSE: OUT) officer plans $100.9K Rule 144 stock sale - Stock Titan

Sep 03, 2026

Aug 26, 2026

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now - TradingView

Aug 26, 2026

Interpace Biosciences will reduce outstanding shares from ~27.7M to ~5.5M - Stock Titan

Aug 26, 2026

Aug 22, 2026

Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotVOLD Alert - vinanet.vn

Aug 22, 2026

Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotVolatility Stop - careplusvn.com

Aug 22, 2026

Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotValue Stock Ideas - siam.in

Aug 22, 2026

Aug 19, 2026

Caribou (CRBU) Quarterly Figures: EPS Comes in Above Forecast in the Latest Reading; Share Move - vinanet.vn

Aug 19, 2026

Caribou (CRBU) Quarterly Figures: EPS Comes in Above Forecast in the Latest Reading; Share Move - vinanet.vn

Aug 19, 2026

3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan

Aug 19, 2026

Aug 18, 2026

PubMatic (NASDAQ: PUBM) details latest insider stock trade - Stock Titan

Aug 18, 2026

Aug 16, 2026

Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelPut Wall - dars.gov.et

Aug 16, 2026

Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelDark Pool Prints - vinanet.vn

Aug 16, 2026

Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelPut Wall - dars.gov.et

Aug 16, 2026

Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelAAII Bearish - dars.gov.et

Aug 16, 2026

Aug 14, 2026

Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Caribou Biosciences (NASDAQ:CRBU) Price Target Cut to $5.00 by Analysts at Bank of America - MarketBeat

Aug 14, 2026

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 14, 2026

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside - TradingView

Aug 14, 2026

Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Aug 14, 2026

Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat

Aug 13, 2026